Keilholz Ulrich
Department of Medicine III, Charity, Campus Benjamin Franklin, Berlin, Germany.
J Immunother. 2008 Jun;31(5):431-9. doi: 10.1097/CJI.0b013e318174a4fe.
A novel approach for cancer immunotherapy is to augment T-cell-mediated immunity by blocking inhibitory signals that suppress T-cell function. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a key negative regulator of T-cell activation. CTLA-4 blockade using anti-CTLA-4 monoclonal antibodies (mAbs) potentiates the T-cell response against tumors, and preliminary data on these agents demonstrate good efficacy and tolerability in the treatment of patients with metastatic melanoma and other cancers. This paper will review data from studies with anti-CTLA-4 mAbs to date, discuss some of the key clinical considerations emerging from early clinical trials with this therapeutic strategy, and provide an overview of ongoing and planned clinical trials for anti-CTLA-4 mAb therapy in metastatic melanoma and other cancers.
一种新型的癌症免疫疗法是通过阻断抑制T细胞功能的抑制性信号来增强T细胞介导的免疫。细胞毒性T淋巴细胞抗原4（CTLA-4）是T细胞活化的关键负调节因子。使用抗CTLA-4单克隆抗体（mAb）阻断CTLA-4可增强T细胞对肿瘤的反应，关于这些药物的初步数据表明，它们在治疗转移性黑色素瘤和其他癌症患者方面具有良好的疗效和耐受性。本文将回顾迄今为止抗CTLA-4 mAb研究的数据，讨论这一治疗策略早期临床试验中出现的一些关键临床考量，并概述转移性黑色素瘤和其他癌症抗CTLA-4 mAb治疗正在进行和计划中的临床试验。
